Celldex acquires two immunotherapy molecules from Amgen
This article was originally published in Scrip
Executive Summary
Celldex Therapeutics has acquired the exclusive rights to two of Amgen's immune modulating molecules to expand its precision targeted immunotherapy platform for an undisclosed sum.